Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2008-07-01
2008-07-01
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S239100, C424S236100, C424S234100, C514S002600
Reexamination Certificate
active
07393537
ABSTRACT:
Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6143306 (2000-11-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6395277 (2002-05-01), Graham
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6620415 (2003-09-01), Donovan
patent: 6689816 (2004-02-01), Fogel
patent: 6955813 (2005-10-01), Brooks et al.
patent: 2003/0234727 (2003-12-01), Perlman
patent: 2004/0157926 (2004-08-01), Heresco-Levy et al.
patent: 2006/0286127 (2006-12-01), Van Schaack et al.
Lang et al. Ann. Neurol. 33: 212-215, 1993.
Granana et al. Seminars in Pediatric Neurology 6: 221-224, Sep. 1999.
Stein et al. J. Clin. Psychiatr. 58: 177-178, Apr. 1997.
Poungvarin et al. J. Med. Assoc. Thailand 78: 281-288, 1995.
Lang et al. Adv. Neurol. 58: 25-32, 1992.
Weinlander et al. J. Psychol. 92: 77-78, 1976 (abstract).
Lee et al. J. Clin. Psychol. 32: 843-844, 1976 (abstract).
Weinlander et al. J. Clin. Psychol. 34: 31-32, 1978 (abstract).
Leckman et al. Am. J. Psychiatry 151: 675-680, 1994.
Greenberg et al. Neurology 54: 142-147, 2000.
Robertson J. Child Psychol. Psychiatr. 35: 597-611, 1994.
Lang A. Neurology 41: 223-228, 1991.
Jankovic J. In: Therapy with Botulinum Toxin. (Ed) Jankovic J. Chapter 39. pp. 503-509, 1994.
Kossoff et al. Pediatric Drugs 3: 355-363, 2001.
Marras et al. Neurology 56: 605-610, Mar. 2001.
Kwak et al. Arch. Neurol. 57: 1190-1193, 2000.
Leckman et al. Am. J. Psychiatry 150: 98-102, 1993.
Frankel et al. Neurology 36: 378-382, 1986.
Giladi N. J. Neurol. Sci. 152: 132-135, 1997 (abstract).
Naver et al. Eur. J. Neurol. 7: 55-62, Jan. 2000.
Callaway et al. Sem. Cutan. Med. Surg. 20: 127-136, Jun. 2001.
Schapiro. Pediatr. Nursing 28: 243-253, May-Jun. 2002.
Pauls et al. Arch. Gen. Psychiatry 43: 1180-1182, 1986.
Dabrowski et al. Dev. Med. Child Neurol. 47: 636-639, 2005.
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 40: 1332-1336, 1990.
Awad et al. J. Chil. Neurol. 14: 316-319, 1999.
George et al. Ann. Otol. Rhinol. Laryngol. 101: 888-892, 1992, abstract.
Wohlfarth et al. Naunyn Schmiedeberg's Arch. Pharmacol. 355: 335-340, 1997.
Ahn et al. Plast. Reconstr. Surg. 105: 778-784, 2002, abstract.
Matarasso SL Dermatol. Surg. 29: 7-13, 2003, abstract.
Berardelli et al. Ital. J. Neurol. Sci. 18: 261-269, 1997.
Arezzo et al. Pain Med. 2: 239, # 202, Sep. 2001, abstract.
Schantz, Edward J. et al., Properties and Use of Boulinum Toxin and Other Microbial Neurotoxins in Medicine;Microbiol Review; Mar. 1992; 56 (1); pp. 80-99.
Singh, Bal Ram; Critical Aspects of Bacterial Protein Toxins;Natural Toxins II; Edited by B. R. Singh et al., Plenum Press, New Yrok, 1996; Chapter 4, pp. 63-84.
Sloop, Richard R. et al., Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use;Neurology; Jan. 1997; 48 (1); pp. 249-253.
Wiegand, H. et al., I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after intramuscular Injection;Naunyn Schmiedebergs Arch Pharmacol; 1976; 292; pp. 161-165.
Zigmond, et al.,Fundamental Neuroscience; 1999 by Academic Press, San Diego, CA; pp. 963-964.
Fung, Lawrence K. et al., Pharmacokinetics of Interstitial Delivery of Carmustine, 4-Hydroperoxycyclophosphamide, and Paclitaxel from a Biodegradable Polymer implant in the Monkey Brain;Cancer Research; 58, Feb. 15, 1998; pp. 672-684.
Guyton, Arthur C. et al.,Textbook of Medical Physiology 10thed; W.B. Saunders Company; pp. 685-697.
Habermann, E., I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord;Naunyn Schmiedeberg's Arch. Pharmacol; 1974; (281); pp. 47-56.
Habermann, E., Inhibition by tetanus and botulinum A toxin of the release of {3H}noradrenaline and {3H}GABA from rat brain homogenate;Experientia; Mar. 15, 1988, 44(3) pp. 224-226.
Habermann, E. et al., Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain;J Neurochem; vol. 51, No. 2 1988; pp. 522-527.
Jankovic, Joseph; Botulinum Toxin in the Treatment of Dystonic Tics;Movment Disorders; vol. 9, No. 3, 1994; pp. 347-349.
Jankovic, Joseph; Botulinum Toxin in the Treatment of Tics Associated with Tourette's Syndrome;Neurology; Apr. 1993; 43(4 Suppl 2); A310; Abstract.
Jankovic, Joseph et al.,Therapy with Botulinum Toxin; Marcel Dekker, Inc.; pp. 5 and 150.
Krauss, Joachim K. et al., Severe Motor Tics Causing Cervical Myelopathy in Tourette's Syndrome;Movement Disorders; vol. 11, No. 5, 1996; pp. 563-565.
Kudelko, K.M. et al., Successful treatment of recalcitrant restless legs syndrome with botulinum toxin A;Movment Disorders; 2002; 17 (Suppl 5); S242 ABS p. 779.
Marjama-Lyons, Jill et al., Tremor-Predominant Parkinson's Disease;Drugs&Aging; Apr. 2000; 16 (4) pp. 273-278.
Moyer, Elizabeth et al., Botulinyum Toxin Type B: Experimental and Clinical Experience;Therapy with Botulinum Toxin; In: Jankovic J. ed.; pp. 71-85.
Naumann, Markus et al., Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions;European Journal of Neurology; 1999, vol. 6 (suppl 4) pp. S111-S115.
Pearce, Bruce et al., Pharmacologic Characterization of Botulinum toxin for Basic Science and Medicine;Toxicon; 1997; 35 (9); pp. 1373-1412.
Ragona, Rosario M. et al., Management of Parotid Sialocele With Botulinum Toxin;Laryngoscope; 109; Aug. 1999 (8); pp. 1344-1346.
Sanchez-Prieto, Jose et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes;Eur J Biochem; Jun. 1987; 165 (3); pp. 675-681.
Aoki, K.R. et al., Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions;European Journal Neurology; 2001; 8 (Suppl 5):pp. 21-29.
Aoki, K.R.; Physiology and Pharmacology of Therapeutic Botulinum Neurotoxins; In: Kreyden OP, ed.Hyperhidrosis and Botulinum Toxin in Dermatology; Current Problems in Dermatology: Basel, Karger; 2002; 30: pp. 107-116.
Bigalke, Hans et al., Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture;Brain Res; 1985; 360: pp. 381-424.
Bigalke, H. et al., Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord;Naunyn Schmiedebergs Arch Pharmacol; 1981; 316; pp. 244-251.
Binz, Thomas et al., The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins;J Biochem; (Tokyo) Jun. 5, 1990; 265(16); pp. 9153-9158.
Boyd, R.S. et al., The insulin secreting B-cell line, HIT-15, contains SNAP-25 which is a target for botulinum neurotoxin-A;Mov. Disorders; May 1995; 10(3); 376.
Brem, Henry et al., Placebo-controlled trial safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas;The Lancet;vol. 345; Apr. 22, 1995; pp. 1008-1012.
Brin, Mitchell F. et al., Botulinum Toxin Type A: Pharmacology; In: Mayer Nathaniel H, ed.Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin; 2002; pp. 110-124.
Chappell, Phillip et al., Fut
Allergan Inc.
Devi S.
Donovan Stephen
Nassif Claude L.
Voet Martin
LandOfFree
Botulinum toxin for treatment of obsessive compulsive finger... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Botulinum toxin for treatment of obsessive compulsive finger..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum toxin for treatment of obsessive compulsive finger... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2813778